FibroGen seeks to identify and develop innovative drugs with the greatest promise of becoming first-in-class medicines for the treatment of chronic and life-threatening conditions such as anemia, idiopathic pulmonary fibrosis, and pancreatic cancer. The Company’s product candidates leverage the body’s natural pathways allowing investigation of their potential across multiple diseases. FibroGen’s most advanced therapeutic, roxadustat, is an oral small molecule inhibitor of hypoxia-inducible factor (HIF) prolyl hydroxylase, the enzyme that regulates HIF activity and is being developed for treatment of anemia associated with CKD.